Implications of Post-Operative Irrigation Fluid's Osmolarity on the Recurrence of Non-Muscle Invasive Bladder Cancer Following Transurethral Resection

This randomized controlled trial will evaluate the efficacy of three bladder irrigation solutions - distilled water (DW), normal saline (NS), and hypertonic saline (HS) - as continuous bladder irrigation (CBI) following transurethral resection of non-muscle invasive bladder cancer (NMIBC). Short term (6 months) recurrence and progression free survival are mainly evaluated.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bladder (Urothelial, Transitional Cell) Cancer Distilled Water Hypertonic Saline Irrigation Neoplasms Nonmuscle Invasive Bladder Cancer Normal Saline

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Ain Shams University

Cairo, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients of non-muscle invasive urinary bladder urothelial carcinoma amenable for complete resection

Exclusion criteria

Patients with post-operative complications that need prolonged irrigation.
Patient who underwent incomplete resection during TURBT.
When large bladder perforation was suspected during TURBT.
Patients with chronic kidney disease.
Muscle invasive disease

Treatment and study plan

Continuous Bladder Irrigation with distilled water

Drug

Continuous Bladder Irrigation with distilled water post non muscle invasive bladder cancer urethral resection by endoscopy

Continuous Bladder Irrigation with normal saline

Drug

Continuous Bladder Irrigation with normal saline post non muscle invasive bladder cancer urethral resection by endoscopy

Continuous Bladder Irrigation with hypertonic saline

Drug

Continuous Bladder Irrigation with hypertonic saline post non muscle invasive bladder cancer urethral resection by endoscopy

Primary outcomes

Risk of Recurrence

Time frame: 6 months
Risk of progression of bladder cancer

Time frame: 6 months

Sponsors and collaborators

Lead sponsor

Ain Shams University

Other

Registry information

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2025
First posted: Dec 12, 2025
Registry last updated: Dec 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed